Submit manuscript

Prevalence of Venous Thromboembolism in Cholangiocarcinoma Patients Receiving Chemotherapy and Validation of Khorana Score

Panupong Sangsri1, Aumkhae Sookprasert1, Kosin Wirasorn1, Jarin Chindaprasirt1, Piyakarn Watcharenwong1, Thanachai Sanlung1

Affiliation : 1 Medical Oncology Unit, Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand

Background: Khorana score (KS) have used to evaluate the risk of chemotherapy-associated venous thromboembolism (VTE) and provide thromboprophylaxis for high-risk patients. However, the applicability of the score to cholangiocarcinoma (CCA) patients remains unclear due to the limited inclusion of patients with CCA in the score derivation process.
Objective: The primary objective focused on the prevalence of VTE within 180 days and the KS score was externally validated in this particular cohort.
Materials and Methods: This retrospective cohort study was conducted at a tertiary care hospital in Northeastern Thailand between January 2014 and December 2021. The study collected baseline clinical characteristics and laboratory data of patients with CCA undergoing palliative chemotherapy and follow-up data to assess the endpoints.
Results: Among the 402 patients included in the cohort, 48 (11.9%) experienced VTE within 180 days. Consequently, the decision was made to assign 1 point for a primary site of cancer factor in the KS calculation. The KS was found to be significantly associated with VTE incidents, with an odds ratio (OR) of 1.63 (95% CI 1.16, 2.29, p=0.005) and an AUC of 0.616 (95% CI 0.534, 0.698). The presence of VTE and higher KS scores were both associated with a worse prognosis.
Conclusion: CCA should be considered a high-risk tumor type for chemotherapy-associated VTE. The KS has been validated as useful in predicting VTE in this particular tumor type. Additionally, VTE or higher KS were associated with shorter overall survival.

Received 6 February 2024 | Revised 30 May 2024 | Accepted 11 June 2024
DOI: 10.35755/jmedassocthai.2024.S01.S79-S85

Keywords : Cholangiocarcinoma; Chemotherapy; Venous thromboembolism; Khorana score; External validation; Survival


All Articles Download


INFORMATION

Contact info

JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND
4th Floor, Royal Golden Jubilee Building,
2 Soi Soonvijai, New Petchburi road,
Bangkok 10310, Thailand.
Phone: 0-2716-6102, 0-2716-6962
Fax: 0-2314-6305
Email: editor@jmatonline.com

JMed Assoc Thai
MEDICAL ASSOCIATION OF THAILAND
ISSN: 0125-2208 (Print),
ISSN: 2408-1981 (Online)
The content of this site is intended for health professionals.

Submissions

» Online Submissions » Author Guidelines » Copyright Notice » Privacy Statement

Other

» Journal Sponsorship » Site Map » About this Publishing System

© MEDICAL ASSOCIATION OF THAILAND. All Rights Reserved. The content of this site is intended for health professionals.